IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Accounts Receivable of $19.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $20.36M.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$690.00K, a 143.18% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $15.69M, a 15.58% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $6.82M, a 71.76% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $13.11M, a 81.05% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $69.19M, a 46335.57% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $149.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $19.67M 10-Q · filed 2026-08-06 | $35.36M derived: sum of 3 quarters · filed 2026-08-06 | $42.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$690.00K 10-Q · filed 2026-05-07 | $15.00M derived: sum of 2 quarters · filed 2026-05-07 | $21.82M derived: sum of 3 quarters · filed 2026-05-07 | $10.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $22.51M derived: sum of 2 quarters · filed 2026-02-24 | $11.51M derived: sum of 3 quarters · filed 2026-08-06 | $13.11M 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.18M derived: sum of 2 quarters · filed 2026-08-06 | -$2.58M 10-Q · filed 2025-11-06 | $10.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.40M 10-Q · filed 2026-08-06 | $4.17M derived: sum of 3 quarters · filed 2026-08-06 | $28.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.60M 10-Q · filed 2026-05-07 | $15.17M derived: sum of 2 quarters · filed 2026-05-07 | $39.33M derived: sum of 3 quarters · filed 2026-05-07 | $70.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $37.74M derived: sum of 2 quarters · filed 2026-02-24 | $69.11M derived: sum of 3 quarters · filed 2026-02-24 | $69.19M 10-K · filed 2026-02-24 |
| 2024-09-30 | $24.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $55.53M derived: sum of 2 quarters · filed 2025-11-06 | $55.62M 10-Q · filed 2025-11-06 | $55.77M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $31.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $31.45M 10-Q · filed 2025-08-07 | $31.60M derived: sum of 3 quarters · filed 2026-02-24 | $31.57M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $83.00K 10-Q · filed 2025-05-08 | $232.00K derived: sum of 2 quarters · filed 2026-02-24 | $199.00K derived: sum of 3 quarters · filed 2026-02-24 | $232.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $116.00K derived: sum of 2 quarters · filed 2026-02-24 | $149.00K derived: sum of 3 quarters · filed 2026-02-24 | $149.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $33.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |